Ahmed, Gajewski to Receive Top Awards from Cancer Research Institute
Rafi Ahmed, PhD, of Emory University, and Thomas F. Gajewski, MD, PhD, of the University of Chicago, received the highest honors from the Cancer Research Institute for their fundamental contributions to the fields of immunology and cancer immunotherapy during the Institute’s 31<sup>st</sup> Annual Awards Dinner on Tuesday, November 14, at The Plaza Hotel in New York City.
Rafi Ahmed, PhD
Rafi Ahmed, PhD
Rafi Ahmed, PhD, of Emory University, and Thomas F. Gajewski, MD, PhD, of the University of Chicago, received the highest honors from the Cancer Research Institute for their fundamental contributions to the fields of immunology and cancer immunotherapy during the Institute’s 31stAnnual Awards Dinner on Tuesday, November 14, at The Plaza Hotel in New York City.
Ahmed, director of the Emory Vaccine Center, a professor in the Department of Microbiology and Immunology, and an investigator at the Emory Center for AIDS research, will receive the 2017 William B. Coley Award for Distinguished Research in Basic Immunology for his seminal work on immune memory, as well as his definitive studies of the role of PD-1 receptor in T cell exhaustion during chronic infection.
Gajewski, leader of the Immunology and Cancer Program, director of the Human Immunologic Monitoring core facility at the University of Chicago Comprehensive Cancer Center, and a professor in the departments of pathology and medicine, will receive the William B. Coley Award for Distinguished Research in Tumor Immunology. Gajewski’s work has enhanced the understanding of the interactions between tumors, immune cells, and other factors that play a role in the immune response to cancer.
Thomas F. Gajewski, MD, PhD
Thomas F. Gajewski, MD, PhD
Each Coley Award honoree will receive a $5,000 prize and a gold medallion bearing the likeness of Coley.
Also during the awards dinner, Shannon J Turley, PhD, will receive the 2017 Frederick W. Alt Award for New Discoveries in Immunology. The award recognizes a former CRI-Irvington postdoctoral fellow whose research has had a major impact on immunology.
Funded by CRI from 2002-2004, Turley is a principal scientist on the cancer immunology team at Genentech, where she focuses on how stromal cells and immune cells influence each other in the context of inflammation, cancer, fibrosis, and response to immunotherapy.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
